NeuroBo Pharmaceuticals (NASDAQ:NRBO) Coverage Initiated by Analysts at Maxim Group

Maxim Group assumed coverage on shares of NeuroBo Pharmaceuticals (NASDAQ:NRBO) in a report published on Wednesday, Benzinga reports. The brokerage issued a buy rating and a $10.00 price target on the stock.

NeuroBo Pharmaceuticals Trading Up 2.3 %

NASDAQ NRBO opened at $3.93 on Wednesday. NeuroBo Pharmaceuticals has a twelve month low of $2.89 and a twelve month high of $6.75. The firm has a 50-day simple moving average of $4.18 and a 200 day simple moving average of $3.97.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.